123i-Labeled Metaiodobenzylguanidine for Diagnosis of Neuroendocrine Tumors

Reports in Medical Imaging - New Zealand
doi 10.2147/rmi.s4529
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Clinical Translation of a Click-Labeled 18f-Octreotate Radioligand for Imaging Neuroendocrine Tumors

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2016English

Diagnosis and Management of Upper Gastrointestinal Neuroendocrine Tumors

Clinical Endoscopy
MedicineNuclear MedicineRadiologyImagingGastroenterology
2017English

The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors

Pancreas
Internal MedicineEndocrinologyHepatologyMetabolismDiabetes
2010English

Myocardial Iodine-123-Metaiodobenzylguanidine (123i-Mibg) Imaging in Brugada Syndrome * Response

Circulation
Cardiovascular MedicinePhysiologyCardiology
2002English

Embolotherapy for Neuroendocrine Tumors

Digestive Disease Interventions
SurgeryNuclear MedicineRadiologyImagingGastroenterology
2019English

Effects and Safety of 131i-Metaiodobenzylguanidine (MIBG) Radiotherapy in Malignant Neuroendocrine Tumors: Results From a Multicenter Observational Registry

Endocrine Journal
EndocrinologyMetabolismDiabetes
2014English

Promising Developments for Pancreatic Neuroendocrine Tumors

Cancer Discovery
Oncology
2011English

Pancreatic Neuroendocrine Tumors

Revista Espanola de Enfermedades Digestivas
MedicineGastroenterology
2017English

Risk Factors for Pancreatic Neuroendocrine Tumors

Pancreas
Internal MedicineEndocrinologyHepatologyMetabolismDiabetes
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy